Mr. Rene Goehrum reports

BIOSYENT ANNOUNCES APPOINTMENT OF NEW DIRECTOR

BioSyent Inc. has appointed Stephen Wilton to the company's board.

Mr. Wilton brings to BioSyent over 28 years of experience in the pharmaceutical industry. A licensed pharmacist, Mr. Wilton earned a BSc in pharmacy from the University of Toronto and started his career working as a pharmacist in community and hospital pharmacy. After working in medical sales and marketing positions at Eli Lilly Canada he joined AstraZeneca Canada where he enjoyed a long and varied career. While at AstraZeneca, Mr. Wilton held leadership positions in marketing where as executive director he led a team managing a $300-million specialty product portfolio, as well as three other assignments as executive director of business development, executive director of pricing, reimbursment and health care solutions, and director of regulatory affairs.

After his 17-year career at AstraZeneca, Mr. Wilton worked as vice-president of pharmacy affairs for the Canadian Association of Chain Drug Stores representing the interests of owners and pharmacists in the Canadian health care system.

Mr. Wilton, who also holds an MBA from York University (Schulich School of Business), is presently president at Market Access Investment Advisors Inc.

BioSyent also announces the grant of 22,455 incentive stock options to certain employees, officers and directors of the company. These incentive stock options are excercisable at a price of $4.45 up to Jan. 14, 2019.

We seek Safe Harbor.